Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematological Diseases, Non-MalignantHematologic NeoplasmsProtocol groupAcute LeukemiasAnemias, CytopeniasMyeloproliferative neoplasms (MPN) and myelodysplastic neoplasms (MDS)TransplantationDiseaseAcute Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic NeoplasmsStem Cell Transplantation, AllogeneicSubgroupHigh riskLow riskwith Ring SideroblastsICD10C92.0-C92.5-C92.6-C92.7-C92.8-C92.9-C93.0-C93.1-D46.-MeSHLeukemia, Myeloid, AcuteLeukemia, Myelomonocytic, ChronicMyelodysplastic SyndromesSequenceChemotherapyChemo-substanceAzacitidineCytarabineDecitabineDecitabine-CedazuridineGlasdegibLenalidomideMelphalanChemo-substanceAzacitidineCytarabineDecitabineDecitabine-CedazuridineGlasdegibLenalidomideMelphalanChemo-substanceAzacitidineCytarabineDecitabineDecitabine-CedazuridineGlasdegibLenalidomideMelphalanChemo-substanceAzacitidineCytarabineDecitabineDecitabine-CedazuridineGlasdegibLenalidomideMelphalanNo. Substances12 RadiotherapySupportive therapySupportive substanceAciclovirAnti-thymocyte Globulin (Equine)Balanced Crystalloid SolutionCiclosporin ACiprofloxacinDarbepoetinDimetindenEltrombopagEpoetin alfaFilgrastimGranisetronLuspaterceptMethylprednisoloneParacetamolPosaconazoleSupportive substanceAciclovirAnti-thymocyte Globulin (Equine)Balanced Crystalloid SolutionCiclosporin ACiprofloxacinDarbepoetinDimetindenEltrombopagEpoetin alfaFilgrastimGranisetronLuspaterceptMethylprednisoloneParacetamolPosaconazoleSupportive substanceAciclovirAnti-thymocyte Globulin (Equine)Balanced Crystalloid SolutionCiclosporin ACiprofloxacinDarbepoetinDimetindenEltrombopagEpoetin alfaFilgrastimGranisetronLuspaterceptMethylprednisoloneParacetamolPosaconazoleSupportive substanceAciclovirAnti-thymocyte Globulin (Equine)Balanced Crystalloid SolutionCiclosporin ACiprofloxacinDarbepoetinDimetindenEltrombopagEpoetin alfaFilgrastimGranisetronLuspaterceptMethylprednisoloneParacetamolPosaconazoleNo. Substances1239Protocol classificationTherapy classificationalternativecurrent standardIntensityLow doseStandard doseTherapy indicationFirst lineRelapse therapyseveral possibleTherapy phaseTherapy intentioncurative or palliativedisease controlpalliativesupportiveRisksAnemia Hb below 8g/dlAstheniaBleedingColitisConstipationDiarrheaEmetogenicityEmetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaHeadacheHeart FailureHemorrhageHepatotoxicityHyperbilirubinemiaHypertensionIncrease AminotransferasesInfectionsLeukopeniaNeutropeniaPainPneumoniaPyrexiaRashRenal FailureSepsisThrombocytopenia below 50 000/µlThromboembolic EventUpper Respiratory Tract Infection only studiesPublicationAuthorCortes JECraddock CFenaux PGarcia-Manero GGreenberg PHellström-Lindberg ELübbert MMannone LOliva EN Passweg JRPlatzbecker USasaki KSchroeder TStasi RSteensma DStratmann JVillegas ADiseaseAML- oder CMML-Rezidiv nach allogener StammzelltranplantationAML- oder MDS-Rezidiv nach allogener StammzelltranplantationAML oder Hochrisiko MDS, nicht für eine Standard-Induktionschemotherapie geeignet, ECOG 0-2de-novo oder sekundäre AML, mindestens 1 nicht-kurative Vortherapie, über 65 JahreDe novo oder sekundäres myelodyplastisches Syndrom, alle Risikogruppen, ECOG 0-2Drohendes AML- oder MDS-Rezidiv nach allogener Stammzelltranplantation (Spenderchimärismus <80%)Hochrisiko myelodysplastisches Syndrom, ECOG 0-2Intermediär-1 und -2-Risiko oder Hochrisiko MDS, Alter > 60 Jahre, ECOG 0-2Myelodysplastisches Syndrom, Niedrig-/Intermediär-1-Risiko, Thrombozytenwert unter 30.000/μl, ECOG 0-3Myelodysplastisches Syndrom, niedriges - intermediäres Risiko, Epo < 500 mU/mlMyelodysplastisches Syndrom, niedriges - intermediäres Risiko, Epo < 500 mU/ml, Hgb <10 g/dL, niedrige TransfusionsrateMyelodysplastisches Syndrom, niedriges - intermediäres Risiko, Epo < 500 mU/ml, niedrige Transfusionsrate, ECOG 0-1Myelodysplastisches Syndrom, Niedrigrisiko, ECOG 0-2Myelodysplastisches Syndrom mit refraktärer Anämie mit/ohne Sideroblasten, RAEB-I, oder hypoplastisch, ECOG 0-2Myelodysplastisches Syndrom und chronische myelomonozytäre Leukämie, ECOG 0-2primäres myelodysplastisches Syndrom länger als 6 Monate, nicht-transfundierter Hämoglobinwert < 10 g/dl, ECOG 0-2refraktäre Anämie, mit Sideroblasten oder exzessiven Blasten, nichtproliferative CMLrefraktäre Anämie beim myelodysplastischen Syndrom, niedrig-intermediäres Risiko, Epo < 500 mU/ml, niedrige TransfusionsrateTansfusionsabhängige Anämie bei MDS mit Ringsideroblasten, sehr niedriges, niedriges oder intermediäres Risiko nach IPSS-R, kein Ansprechen auf Erythropoetinbasierte Therapie oder nicht dafür geeignet OriginAlbert Ludwigs Universität, Freiburg, deutsche MDS- StudiengruppeARCADE trialAzienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy, EQoL-MDS trialCarl Gustav Carus Technical University of Dresden, Dresden, Germany, RELAZA trialDepartment of Haematology, Nice University Hospital, Groupe Francais des Myelodysplasies (GFM)Department of Hematology, Huddinge University Hospital, Huddinge, SwedenDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, HoustonDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TXDepartment of Medical Sciences, Regina Apostolorum Hospital, Albano LazialeDivision Hematology and Oncology, University of Freiburg Medical Center, Freiburg, GermanyHematology and Oncology, Goethe University, Frankfurt, Frankfurt am Main, GermanyHematology Department, Hospital Clinico San Carlos, Madrid, SpanienHopital Saint-Louis, Assistance Publique-Hopitaux de Paris and Universite Paris 7, Paris, FranceHopitaux Universitaires de Geneve, Geneva, SAKK 33/99Mayo Clinic Rochester, MN; Roswell Park Cancer Institute, Buffalo, NY, ADOPT trialOncology and Clinical Immunology, University of Duesseldorf, Medical Faculty, Duesseldorf, GermanyService d´Hematologie Clinique, Hoptial, Avicenne/Universite Paris, FranceStanford University Cancer Center, CA (ECOG E1996)University of Birmingham, Birmingham, United KingdomUniversity of Texas, MD Anderson Cancer Center, Houston, USAProtocols in Revision 21 protocols foundProtocols under revision.Anti-thymocyte Globulin (Equine) 15 / Ciclosporin 5, Myelodysplastic Syndrome. (PID1766)Azacitidine 100, Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplantation (PID2302)Azacitidine 100, Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplantation, Variant 1. (PID2320)Azacitidine 75 / Lenalidomide 25, Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplantation (PID827)Azacitidine 75, Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplantation. (PID2327)Azacitidine 75, Myelodysplastic Syndrome, High-Risk (PID616)Azacitidine 75, Myelodysplastic Syndrome, Low risk (PID2317)Cytarabine 20 / Glasdegib 100, Acute Myeloid Leukemia and Myelodysplastic Syndrome (PID1674)Darbepoetin alfa 150, Myelodysplastic Syndrome (PID783)Darbepoetin alfa 300 / Filgrastim 300, Myelodysplastic Syndrome (PID838)Darbepoetin alfa 300, Myelodysplastic Syndrome (PID836)Darbepoetin alfa 500, Myelodysplastic Syndrome (PID837)Decitabine 15, Myelodysplastic Syndrome (PID727)Decitabine 20, Myelodysplastic Syndrome (PID904)Decitabine 20, Myelodysplastic Syndrome, Low risk (PID2318)Decitabine-Cedazuridine 135, Myelodysplastic Syndrome (PID2514)Eltrombopag 50, Myelodysplastic Syndrome (PID2513)Epoetin Alfa 40000 / Filgrastim 120, Myelodysplastic Syndrome (PID728)Epoetin Alfa 40000, Myelodysplastic Syndrome (PID841)Luspatercept 1.0, Myelodysplastic Syndrome (PID1603)Melphalan 2, Acute Myeloid Leukemia, over 65 years of age (PID1735)